tandem diabetes care inc - TNDM
TNDM
Close Chg Chg %
24.26 -0.83 -3.42%
Open Market
23.43
-0.83 (3.42%)
Volume: 484.83K
Last Updated:
Mar 26, 2026, 11:03 AM EDT
Company Overview: tandem diabetes care inc - TNDM
TNDM Key Data
| Open $23.81 | Day Range 23.43 - 24.25 |
| 52 Week Range 10.00 - 29.65 | Market Cap $1.66B |
| Shares Outstanding 68.33M | Public Float 67.59M |
| Beta 1.63 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.07 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.99M |
TNDM Performance
| 1 Week | -2.26% | ||
| 1 Month | -4.11% | ||
| 3 Months | 8.55% | ||
| 1 Year | 25.83% | ||
| 5 Years | -70.63% |
TNDM Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
23
Full Ratings ➔
About tandem diabetes care inc - TNDM
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
TNDM At a Glance
Tandem Diabetes Care, Inc.
12400 High Bluff Drive
San Diego, California 92130
| Phone | 1-858-366-6900 | Revenue | 1.01B | |
| Industry | Medical Specialties | Net Income | -204,710,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 7.927% | |
| Fiscal Year-end | 12 / 2026 | Employees | 2,500 | |
| View SEC Filings |
TNDM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.457 |
| Price to Book Ratio | 9.673 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -27.055 |
| Enterprise Value to Sales | 1.612 |
| Total Debt to Enterprise Value | 0.275 |
TNDM Efficiency
| Revenue/Employee | 405,894.40 |
| Income Per Employee | -81,884.00 |
| Receivables Turnover | 6.132 |
| Total Asset Turnover | 1.098 |
TNDM Liquidity
| Current Ratio | 2.547 |
| Quick Ratio | 2.016 |
| Cash Ratio | 1.206 |
TNDM Profitability
| Gross Margin | 52.314 |
| Operating Margin | -7.699 |
| Pretax Margin | -19.736 |
| Net Margin | -20.174 |
| Return on Assets | -22.146 |
| Return on Equity | -97.885 |
| Return on Total Capital | -33.862 |
| Return on Invested Capital | -32.546 |
TNDM Capital Structure
| Total Debt to Total Equity | 289.602 |
| Total Debt to Total Capital | 74.333 |
| Total Debt to Total Assets | 51.001 |
| Long-Term Debt to Equity | 273.895 |
| Long-Term Debt to Total Capital | 70.301 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Tandem Diabetes Care Inc - TNDM
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 801.22M | 747.72M | 940.20M | 1.01B | |
Sales Growth
| +14.00% | -6.68% | +25.74% | +7.93% | |
Cost of Goods Sold (COGS) incl D&A
| 400.56M | 393.84M | 465.34M | 483.89M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 14.33M | 15.71M | 16.61M | 17.67M | |
Depreciation
| 12.33M | 13.81M | 14.71M | 15.17M | |
Amortization of Intangibles
| 2.00M | 1.90M | 1.90M | 2.50M | |
COGS Growth
| +18.43% | -1.68% | +18.15% | +3.99% | |
Gross Income
| 400.66M | 353.88M | 474.87M | 530.85M | |
Gross Income Growth
| +9.90% | -11.68% | +34.19% | +11.79% | |
Gross Profit Margin
| +50.01% | +47.33% | +50.51% | +52.31% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 462.46M | 508.36M | 573.99M | 608.97M | |
Research & Development
| 126.78M | 155.85M | 184.17M | 174.84M | |
Other SG&A
| 335.68M | 352.50M | 389.82M | 434.13M | |
SGA Growth
| +35.26% | +9.92% | +12.91% | +6.09% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 30.89M | 78.75M | 1.27M | 109.14M | |
EBIT after Unusual Expense
| (92.70M) | (233.23M) | (100.39M) | (187.26M) | |
Non Operating Income/Expense
| 6.06M | 22.86M | 15.94M | (5.11M) | |
Non-Operating Interest Income
| 6.06M | 22.86M | 17.99M | 9.09M | |
Equity in Earnings of Affiliates
| - | - | (2.05M) | (14.19M) | - |
Interest Expense
| 6.21M | 9.88M | 7.42M | 7.91M | |
Interest Expense Growth
| +2.78% | +59.18% | -24.96% | +6.64% | |
Gross Interest Expense
| 6.21M | 9.88M | 7.42M | 7.91M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (92.85M) | (220.25M) | (91.87M) | (200.27M) | |
Pretax Income Growth
| -683.94% | -137.21% | +58.29% | -117.99% | |
Pretax Margin
| -11.59% | -29.46% | -9.77% | -19.74% | |
Income Tax
| 1.74M | 2.36M | 4.16M | 4.44M | |
Income Tax - Current - Domestic
| 1.44M | 653.00K | 1.78M | 488.00K | |
Income Tax - Current - Foreign
| 298.00K | 1.70M | 2.38M | 3.95M | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | (2.05M) | (14.19M) | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (94.59M) | (222.61M) | (96.03M) | (204.71M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (94.59M) | (222.61M) | (96.03M) | (204.71M) | |
Net Income Growth
| -707.70% | -135.33% | +56.86% | -113.18% | |
Net Margin Growth
| -11.81% | -29.77% | -10.21% | -20.17% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (94.59M) | (222.61M) | (96.03M) | (204.71M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (94.59M) | (222.61M) | (96.03M) | (204.71M) | |
EPS (Basic)
| -1.4747 | -3.4264 | -1.4671 | -3.0424 | |
EPS (Basic) Growth
| -696.80% | -132.35% | +57.18% | -107.38% | |
Basic Shares Outstanding
| 64.15M | 64.97M | 65.45M | 67.28M | |
EPS (Diluted)
| -1.4747 | -3.4264 | -1.4671 | -3.0424 | |
EPS (Diluted) Growth
| -709.63% | -132.35% | +57.18% | -107.38% | |
Diluted Shares Outstanding
| 64.15M | 64.97M | 65.45M | 67.28M | |
EBITDA
| (47.48M) | (138.76M) | (82.52M) | (60.46M) | |
EBITDA Growth
| -230.09% | -192.27% | +40.53% | +26.74% | |
EBITDA Margin
| -5.93% | -18.56% | -8.78% | -5.96% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 31.30 | |
| Number of Ratings | 23 | Current Quarters Estimate | -0.441 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.757 | |
| Last Quarter’s Earnings | -0.009 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.46 | Next Fiscal Year Estimate | 0.024 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 20 | 20 | 21 | 20 |
| Mean Estimate | -0.44 | -0.29 | -0.76 | 0.02 |
| High Estimates | -0.35 | -0.17 | -0.40 | 1.09 |
| Low Estimate | -0.54 | -0.39 | -1.14 | -1.04 |
| Coefficient of Variance | -13.22 | -25.93 | -26.99 | 1,742.57 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 10 | 8 | 7 |
| OVERWEIGHT | 2 | 2 | 2 |
| HOLD | 11 | 15 | 15 |
| UNDERWEIGHT | 0 | 0 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Tandem Diabetes Care Inc - TNDM
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Tandem Diabetes Care Inc - TNDM
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 20, 2026 | Brian B. Hansen EVP & Chief Legal Officer | 23,728 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Mark Novara EVP & CHIEF COMMERCIAL OFFICER | 380 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Rick Carpenter Chief Technology Officer | 1,437 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Rick Carpenter Chief Technology Officer | 25,274 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.95 per share | 478,942.30 |
| Feb 20, 2026 | Rick Carpenter Chief Technology Officer | 25,778 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Rick Carpenter Chief Technology Officer | 24,881 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.95 per share | 471,494.95 |
| Feb 20, 2026 | Rick Carpenter Chief Technology Officer | 25,689 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Brian B. Hansen EVP & Chief Legal Officer | 5,484 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Brian B. Hansen EVP & Chief Legal Officer | 1,437 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Brian B. Hansen EVP & Chief Legal Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Brian B. Hansen EVP & Chief Legal Officer | 23,276 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.95 per share | 441,080.20 |
| Feb 20, 2026 | John F. Sheridan PRESIDENT & CEO; Director | 123,071 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Brian B. Hansen EVP & Chief Legal Officer | 22,631 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.95 per share | 428,857.45 |
| Feb 20, 2026 | Brian B. Hansen EVP & Chief Legal Officer | 23,223 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Brian B. Hansen EVP & Chief Legal Officer | 21,786 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.95 per share | 412,844.70 |
| Feb 20, 2026 | Brian B. Hansen EVP & Chief Legal Officer | 22,005 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | John F. Sheridan PRESIDENT & CEO; Director | 29,911 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | John F. Sheridan PRESIDENT & CEO; Director | 5,472 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | John F. Sheridan PRESIDENT & CEO; Director | 124,691 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.95 per share | 2,362,894.45 |
| Feb 20, 2026 | John F. Sheridan PRESIDENT & CEO; Director | 127,091 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |